IKDC or KOOS? Which measures symptoms and disabilities most important to postoperative articular cartilage repair patients?

BACKGROUND: The relevance of knee-specific subjective measures of outcome to patients has not been evaluated for cartilage repair procedures. PURPOSE: The aim of this study was to identify which instrument out of the Knee injury Osteoarthritis Outcome Score and the International Knee Documentation Committee Subjective Knee Form measures symptoms and disabilities most important to postoperative articular cartilage repair patients. STUDY DESIGN: Cross-sectional study; Level of evidence, 3. METHODS: Data were collected from 58 participants of an Internet knee forum via a self-reported online questionnaire consisting of demographic and surgical data, the Tegner activity scale, and 49 consolidated items from the Knee injury Osteoarthritis Outcome Score and the International Knee Documentation Committee Subjective Knee Form. Item importance, frequency, and frequency-importance product were calculated. RESULTS: Overall, the International Knee Documentation Committee Subjective Knee Form was the highest scoring instrument in all categories. However, 2 of the Knee injury Osteoarthritis Outcome Score subscales ("function in sport and recreation" and "knee-related quality of life") scored higher on mean importance and frequency-importance product than the overall International Knee Documentation Committee Subjective Knee Form score. CONCLUSION: The International Knee Documentation Committee Subjective Knee Form provided the best overall measure of symptoms and disabilities that are most important to this population of postoperative articular cartilage repair patients. This brings into question the validity of using the Knee injury Osteoarthritis Outcome Score in shorter-term--less than 10 years--studies. Issues related to sports activity appear to be highly valued and very pertinent to evaluation of outcomes for this patient group

Poly(2-ethyl-(2-pyrrolidone) methacrylate) and hyaluronic acid-based hydrogels for the engineering of a cartilage-like tissue using bovine articular chondrocytes

Poly(2-ethyl-(2-pyrrolidone)methacrylate)-hyaluronic acid hydrogels based on the free radical polymerization of 2-ethyl-(2-pyrrolidone)methacrylate combined with hyaluronic acid, using N,N′-methylenebisacrylamide or triethylene glycol dimethacrylate, as cross-linking agents, were considered for tissue engineering applications. Bovine articular chondrocytes were seeded onto the poly(2-ethyl-(2-pyrrolidone)methacrylate)-hyaluronic acid hydrogels, under orbital agitation, for a total of 40 days. The engineered cell-constructs were characterized according to cell proliferation, morphology and distribution as well as the biochemical composition of the tissue formed. The chondrocytes were found to be attached and presented a typical spherical morphology. Cells were able to proliferate and synthesize a hyaline-like matrix rich in glycosaminoglycans and collagen type II which were mainly located on the superficial area. Increased content of individual components poly(2-ethyl-(2-pyrrolidone)methacrylate) and hyaluronic acid, in triethylene glycol dimethacrylate-cross-linked networks led to enhanced cell distribution and total glycosaminoglycans content, supporting their potential application for the repair of cartilaginous tissues.Peer Reviewe

Matrix-Applied Characterized Autologous Cultured Chondrocytes Versus Microfracture: Two-Year Follow-up of a Prospective Randomized Trial

Background: Randomized controlled trials studying the efficacy and safety of matrix-applied characterized autologous cultured chondrocytes (MACI) versus microfracture (MFX) for treating cartilage defects are limited. Purpose: To compare the clinical efficacy and safety of MACI versus MFX in the treatment of patients with symptomatic cartilage defects of the knee. Study Design: Randomized controlled clinical trial; Level of evidence, 1. Methods: Patients enrolled in the SUMMIT (Demonstrate the Superiority of MACI implant to Microfracture Treatment) trial had >= 1 symptomatic focal cartilage defect (Outerbridge grade III or IV; >= 3 cm(2)) of the femoral condyles or trochlea, with a baseline Knee Injury and Osteoarthritis Outcome Score (KOOS) pain value Results: Of the 144 patients treated, 137 (95%) completed the 2-year assessment. Patients had a mean age of 33.8 years and a mean lesion size of 4.8 cm(2). The mean KOOS pain and function subscores from baseline to 2 years were significantly more improved with MACI than with MFX (pain: MACI, 37.0 to 82.5 vs MFX, 35.5 to 70.9; function: MACI, 14.9 to 60.9 vs MFX, 12.6 to 48.7; P = .001). A significant improvement in scores was also observed on the KOOS subscales of activities of daily living (MACI, 43.5 to 87.2 vs MFX, 42.6 to 75.8; P = 3 cm(2) in size using MACI was clinically and statistically significantly better than with MFX, with similar structural repair tissue and safety, in this heterogeneous patient population. Moreover, MACI offers a more efficacious alternative than MFX with a similar safety profile for the treatment of symptomatic articular cartilage defects of the knee

Matrix-Applied Characterized Autologous Cultured Chondrocytes Versus Microfracture: Two-Year Follow-up of a Prospective Randomized Trial.

BACKGROUND: Randomized controlled trials studying the efficacy and safety of matrix-applied characterized autologous cultured chondrocytes (MACI) versus microfracture (MFX) for treating cartilage defects are limited. PURPOSE: To compare the clinical efficacy and safety of MACI versus MFX in the treatment of patients with symptomatic cartilage defects of the knee. STUDY DESIGN: Randomized controlled clinical trial; Level of evidence, 1. METHODS: Patients enrolled in the SUMMIT (Demonstrate the Superiority of MACI implant to Microfracture Treatment) trial had ≥1 symptomatic focal cartilage defect (Outerbridge grade III or IV; ≥3 cm(2)) of the femoral condyles or trochlea, with a baseline Knee Injury and Osteoarthritis Outcome Score (KOOS) pain value <55. The co-primary efficacy endpoint was the change in the KOOS pain and function subscores from baseline to 2 years. Histological evaluation and magnetic resonance imaging (MRI) assessments of structural repair tissue, treatment failure, the remaining 3 KOOS subscales, and safety were also assessed. RESULTS: Of the 144 patients treated, 137 (95%) completed the 2-year assessment. Patients had a mean age of 33.8 years and a mean lesion size of 4.8 cm(2). The mean KOOS pain and function subscores from baseline to 2 years were significantly more improved with MACI than with MFX (pain: MACI, 37.0 to 82.5 vs MFX, 35.5 to 70.9; function: MACI, 14.9 to 60.9 vs MFX, 12.6 to 48.7; P = .001). A significant improvement in scores was also observed on the KOOS subscales of activities of daily living (MACI, 43.5 to 87.2 vs MFX, 42.6 to 75.8; P < .001), knee-related quality of life (MACI, 18.8 to 56.2 vs MFX, 17.2 to 47.3; P = .029), and other symptoms (MACI, 48.3 to 83.7 vs MFX, 44.4 to 72.2; P < .001) for patients treated with MACI compared with MFX. Repair tissue quality was good as assessed by histology/MRI, but no difference was shown between treatments. A low number of treatment failures (nonresponders: MACI, 12.5% vs MFX, 31.9%; P = .016) and no unexpected safety findings were reported. CONCLUSION: The treatment of symptomatic cartilage knee defects ≥3 cm(2) in size using MACI was clinically and statistically significantly better than with MFX, with similar structural repair tissue and safety, in this heterogeneous patient population. Moreover, MACI offers a more efficacious alternative than MFX with a similar safety profile for the treatment of symptomatic articular cartilage defects of the knee

Handbook of LHC Higgs Cross Sections: 4. Deciphering the Nature of the Higgs Sector

868 pages, 295 figures, 248 tables and 1642 citations. Working Group web page: https://twiki.cern.ch/twiki/bin/view/LHCPhysics/LHCHXSWGThis Report summarizes the results of the activities of the LHC Higgs Cross Section Working Group in the period 2014-2016. The main goal of the working group was to present the state-of-the-art of Higgs physics at the LHC, integrating all new results that have appeared in the last few years. The first part compiles the most up-to-date predictions of Higgs boson production cross sections and decay branching ratios, parton distribution functions, and off-shell Higgs boson production and interference effects. The second part discusses the recent progress in Higgs effective field theory predictions, followed by the third part on pseudo-observables, simplified template cross section and fiducial cross section measurements, which give the baseline framework for Higgs boson property measurements. The fourth part deals with the beyond the Standard Model predictions of various benchmark scenarios of Minimal Supersymmetric Standard Model, extended scalar sector, Next-to-Minimal Supersymmetric Standard Model and exotic Higgs boson decays. This report follows three previous working-group reports: Handbook of LHC Higgs Cross Sections: 1. Inclusive Observables (CERN-2011-002), Handbook of LHC Higgs Cross Sections: 2. Differential Distributions (CERN-2012-002), and Handbook of LHC Higgs Cross Sections: 3. Higgs properties (CERN-2013-004). The current report serves as the baseline reference for Higgs physics in LHC Run 2 and beyond